Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Impact of Continuous Renal Replacement Therapy on the Outcomes of Burn Patients With Early Phase of Sepsis (CRRT)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2011 by Southwest Hospital, China.
Recruitment status was  Active, not recruiting
Information provided by (Responsible Party):
Zhiqiang Yuan, Southwest Hospital, China Identifier:
First received: December 20, 2011
Last updated: December 28, 2011
Last verified: December 2011

The purpose of this study is to determine if early application of CRRT will result in an improvement of clinical outcomes of burn patients during the early phase of sepsis

Condition Intervention
Procedure: Continuous Renal Replacement Therapy

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Controlled Trial on the Impact of Early Application of CRRT on the Outcomes of Burn Patients With Early Phase of Sepsis

Resource links provided by NLM:

Further study details as provided by Southwest Hospital, China:

Primary Outcome Measures:
  • Changes in serum cytokine concentrations and clearance [ Time Frame: 96 hours ] [ Designated as safety issue: No ]
    0, 6, 12 , 24, 48, 96 hours post CRRT

Secondary Outcome Measures:
  • 28 and 90 days survival [ Time Frame: 90 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: December 2011
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Control group Procedure: Continuous Renal Replacement Therapy
Patients will be randomized to either arm :early HV-crrt(50ml/kg/h) or Control group
Experimental: early HV-crrt Procedure: Continuous Renal Replacement Therapy
Patients will be randomized to either arm :early HV-crrt(50ml/kg/h) or Control group

Detailed Description:

The impact of Continuous Renal Replacement Therapy (CRRT) on the outcomes of patients with sepsis is controversial, and there is no consensus for the timing and dose of CRRT may improve the outcomes. The purpose of this prospective randomized study is to assess the effect of different CRRT intensity (25ml/kg/h or 50ml/kg/h) on the outcomes of burn patients with early phase of sepsis


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with documented sepsis
  • clinically identified focus of infection associated with at least 2 SIRS -criteria and one or more sepsis-induced organ failures within the 24 hours -prior to inclusion
  • age 18 to 70 years
  • severe burned patients with 50% < TBSA < 85%

Exclusion Criteria:

  • cirrhosis child class C
  • too high APACHE II & SOFA score at admission
  • age over 70 years
  • were presence of a malignant tumor, chronic renal insufficiency (serum creatinine > 133 µmol/L), moribund state, receiving immunosuppressive therapy or receiving any kind of renal replacement therapy before randomization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01501097

China, Chongqing
Southwest Hospital
Chongqing, Chongqing, China, 400038
Sponsors and Collaborators
Southwest Hospital, China
  More Information

No publications provided

Responsible Party: Zhiqiang Yuan, Associate Professor, Southwest Hospital, China Identifier: NCT01501097     History of Changes
Other Study ID Numbers: SWHCBS01
Study First Received: December 20, 2011
Last Updated: December 28, 2011
Health Authority: China: Food and Drug Administration

Additional relevant MeSH terms:
Pathologic Processes
Systemic Inflammatory Response Syndrome
Wounds and Injuries processed this record on November 24, 2014